Skip to main content
. 2020 Apr 16;5:20200008. doi: 10.2490/prm.20200008

Table 1.  Characteristics of subjects in the rPMS and non-rPMS groups.

rPMS non-rPMS
Patient no. 1 2 3 4 5 6 Mean ± SD 7 8 9 10 11 12 Mean ± SD
Age (years) 69 87 74 78 72 73 75.5 ± 6.4 71 77 53 59 46 69 62.5 ± 11.8 *
Sex F M M M M M - M F M M M M -
Height (cm) 153.0 164.0 155.0 163.0 170.0 164.0 161.5 ± 6.3 158.6 148.0 170.0 165.0 154.5 162.0 159.7 ± 7.8
Weight (kg) 40.2 56.0 55.8 56.8 68.6 69.6 57.8 ± 10.7 53.2 40.7 89.6 66.3 73.8 74.8 66.4 ± 17.3
BMI (kg/m2) 17.2 20.8 23.2 21.4 23.7 25.9 22.0 ± 3.0 21.1 18.6 31.0 24.4 30.9 28.5 25.8 ± 5.2
Lesion area R thalamic
hemorrhage
R thalamic hemorrhage R putamen hemorrhage L MCA infarction R MCA infarction L MCA infarction - L MCA infarction R thalamic hemorrhage L putamen hemorrhage R thalamic hemorrhage R BAD L corona radiata infarction -
NIHSS 8 10 14 7 12 12 10.5 ± 2.7 16 16 18 15 7 6 13.0 ± 5.1
NIHSS LL 2 2 4 3 2 2 2.5 ± 0.8 2 4 3 3 2 2 2.6 ± 0.8
Total PT days 12 16 12 11 11 15 12.8 ± 2.1 12 10 10 14 15 11 12.0 ± 2.1
Total PT units 25 29 29 14 20 36 25.5 ± 7.7 19 20 15 28 33 19 22.3 ± 6.7
Days until first PT 3 2 2 2 1 2 2.0 ± 0.6 2 3 3 2 4 2 2.7 ± 0.8
Days until baseline measurement 4 3 4 3 3 4 3.5 ± 0.5 3 3 4 3 4 2 3.1 ± 0.8
Days until measurement 2 weeks later 18 21 18 17 14 18 17.7 ± 2.3 17 17 19 18 20 18 18.2 ± 1.2
Days until start of rPMS 4 4 5 3 3 4 3.8 ± 0.8 - - - - - - -
CRP peak value
(mg/dL)
0.22 0.24 0.06 15.65 0.18 7.06 3.09 ± 6.38 10.64 23.05 4.55 1.77 No data 0.44 8.09 ± 9.24
ALB minimum
value (g/dL)
3.5 2.8 3.5 3.1 3.1 3.0 3.2 ± 0.3 1.9 2.4 3.6 2.9 No data 4.1 3.0 ± 0.9

SD, standard deviation; F, female; M, male; BMI, body mass index; R, right; L, left; MCA, middle cerebral artery; BAD, branch atheromatous disease; LL, lower limb motor score on the paretic side; PT, physical therapy; CRP, C-reactive protein; ALB, albumin.

CRP and ALB levels were not measured in Patient 11 during the experimental period.

*P < 0.05 vs. rPMS group.